Evidence mapPaperPMID 36064604Full record

Trial reportStem cell research & therapy2022

Translational development of ABCB5

Andreas Kerstan, Kathrin Dieter, Elke Niebergall-Roth, Sabrina Klingele, Michael Jünger, Christoph Hasslacher, Georg Daeschlein, Lutz Stemler, Ulrich Meyer-Pannwitt, Kristin Schubert and 17 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Stem cell research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03267784 (An Interventional, Multicenter, Single Arm, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-DFU on Wound Healing of Diabetic Neuropathic Ulcer), which is not on this map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03267784 phase1 / phase2completednot on this map

An Interventional, Multicenter, Single Arm, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-DFU on Wound Healing of Diabetic Neuropathic Ulcer (DFU)

TypeinterventionalSponsorRHEACELL GmbH & Co. KGRan2017 to 2020Enrolled23ConditionsDiabetic Neuropathic UlcerArmsallo-APZ2-DFU
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 9 institutions in 3 countries.

Andreas Kerstan *Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.
Kathrin Dieter *RHEACELL GmbH & Co. KG, Heidelberg, Germany.
Elke Niebergall-Roth *TICEBA GmbH, Im Neuenheimer Feld 517, 69120, Heidelberg, Germany.
Sabrina KlingeleTICEBA GmbH, Im Neuenheimer Feld 517, 69120, Heidelberg, Germany.
Michael JüngerDepartment of Dermatology, University Hospital Greifswald, Greifswald, Germany.
Christoph HasslacherClinical Study Center St. Josefskrankenhaus, Heidelberg, Germany.
Georg DaeschleinDepartment of Dermatology, University Hospital Greifswald, Greifswald, Germany.
Lutz StemlerDiabetologikum DDG Ludwigshafen, Ludwigshafen, Germany.
Ulrich Meyer-PannwittDepartment of Clinical Research and Development, MARE Clinic, Kiel, Germany.
Kristin Schubertmedamed GmbH, Leipzig, Germany.
Gerhard KlausmannStudienzentrum Aschaffenburg, Aschaffenburg, Germany.
Titus RaabDiabetologikum Raab, Kassel, Germany.
Matthias GoebelerDepartment of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.
Korinna KraftRHEACELL GmbH & Co. KG, Heidelberg, Germany.
Jasmina EsterlechnerTICEBA GmbH, Im Neuenheimer Feld 517, 69120, Heidelberg, Germany.
Hannes M SchröderRHEACELL GmbH & Co. KG, Heidelberg, Germany.
Samar SadeghiTICEBA GmbH, Im Neuenheimer Feld 517, 69120, Heidelberg, Germany.
Seda BallikayaTICEBA GmbH, Im Neuenheimer Feld 517, 69120, Heidelberg, Germany.
Martin GasserDepartment of Surgery, University Hospital Würzburg, Würzburg, Germany.
Ana M Waaga-GasserDepartment of Surgery, University Hospital Würzburg, Würzburg, Germany.
George F MurphyDepartment of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Dennis P OrgillDivision of Plastic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Natasha Y FrankDepartment of Medicine, VA Boston Healthcare System, Boston, MA, USA.
Christoph GanssRHEACELL GmbH & Co. KG, Heidelberg, Germany.
Karin Scharffetter-KochanekDepartment of Dermatology and Allergic Diseases, University Hospital, Ulm, Germany.
Markus H Frank *Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Mark A Kluth *RHEACELL GmbH & Co. KG, Heidelberg, Germany. andreas.kluth@ticeba.com.ORCID 0000-0003-0764-4645
Brigham and Women's Hospital · USRheacell (Germany) · DEUniversitätsklinikum Würzburg · DEUniversitätsmedizin Greifswald · DEEdith Cowan University · AUHeidelberg University · DEKlinikum Kassel · DEKlinikum Ludwigshafen · DEUniversity Hospital Ulm · DE

Funding

Skin-Intrinsic Immunosuppressive Mesenchymal Stem Cells and aGVHDR01HL161087 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · 2022 to 2025
$1.7M
ABCB5-positive stem cells for LSCD therapyR01EY025794 · BOSTON CHILDREN'S HOSPITAL · 2025 to 2025
$762k
BLRD VA I01 BX000516NEI NIH HHS R01 EY025794NEI NIH HHS R24 EY028767NEI NIH HHS R24EY028767NEI NIH HHS RO1EY025794NHLBI NIH HHS 1R01HL161087NHLBI NIH HHS R01 HL161087RRD VA I01 RX000989
6 · The paper itself

Abstract

backgroundWhile rapid healing of diabetic foot ulcers (DFUs) is highly desirable to avoid infections, amputations and life-threatening complications, DFUs often respond poorly to standard treatment. GMP-manufactured skin-derived ABCB5

methodsThe angiogenic potential of ABCB5

resultsHypoxic incubation of ABCB5

conclusionsThe present observations identify GMP-manufactured ABCB5

trial registrationClinicalTrials.gov, NCT03267784, Registered 30 August 2017, https://clinicaltrials.gov/ct2/show/NCT03267784.

Indexed as

ATP Binding Cassette Transporter, Subfamily BDiabetic FootMesenchymal Stem CellsMesenchymal Stem Cell TransplantationNeovascularization, PhysiologicAnimalsDermisDiabetes MellitusHumansIschemiaMiceNeovascularization, PathologicRNA, MessengerVascular Endothelial Growth Factor AWound HealingABCB5 protein, humanABCB5 protein, mouseATP Binding Cassette Transporter, Subfamily BRNA, MessengerVascular Endothelial Growth Factor AABCB5Advanced-therapy medicinal productAngiogenesisChronic woundDiabetic foot ulcerMesenchymal stem cellsWound healing

Identifiers

PMID36064604
PMCPMC9444095
OpenAlexW4294647404

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.